Ann: Novogen submits IND Application to the FDA for Cantrixil-NRT.AX, page-64

No one appears to be pumping it qqqq - maybe the plan is to let the drugs do the talking...

Just re-read that release:

The IND submission includes a comprehensive package of data, encompassing preclinical pharmacology and toxicity, manufacturing, quality control and clinical development plans. Novogen will be able to move forward to the next step of setting up the clinical trials program thirty days after submission, unless FDA reviewers have questions or concerns which cannot be resolved during that time.

This gives an updated timetable - 30 days lands us around the 11th of September (all going well).

So we know the full year is due on the 31st August and we should be expecting news one way or the other by the say the 12th of September - the news flow going forward looks better - and without pumping as an investor you don't need to strip out the hype therefore you can have greater confidence thus creating more trust IMHO (IF they choose to not pump).. with greater news flow of material value the sp should improve without the big spikes (not the best news for specs I guess but maybe specs aren't the best news for NRT to be taken seriously)...